Pentoxifylline, Inflammation, and Endothelial Function in HIV-Infected Persons: A Randomized, Placebo-Controlled Trial

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Gupta, Samir K ^a   Mi, Deming ^a   Dubé, Michael P ^b   Saha, Chandan K ^a   Johnson, Raymond M ^a   Stein, James H ^c   Clauss, Matthias A ^a   Mather, Kieren J ^a   Desta, Zeruesenay ^a   Liu, Ziyue ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOXIFYLLINE; PLACEBO; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CELL FUNCTION; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SCREENING; ENDOTHELIUM; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERKALEMIA; HYPOKALEMIA; IMMUNOMODULATION; INFLAMMATION; LIVER FUNCTION TEST; MALE; NEUTROPENIA; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SIDE EFFECT; SYSTEMIC INFLAMMATION; TREATMENT DURATION; UPREGULATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; ENDOTHELIUM, VASCULAR; FEMALE; HIV INFECTIONS; HUMANS; MALE; PENTOXIFYLLINE; SEX FACTORS; TREATMENT OUTCOME; VASCULITIS; YOUNG ADULT;

EID: 84876021960     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060852     Document Type: Article

References (26)

1. Triant VA, Lee H, Hadigan C, Grinspoon SK, (2007) Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 92: 2506-2512.
2. Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, et al. (2007) Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 44: 1625-1631.
3. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, et al. (2007) Class of antiretroviral drugs and the risk of myocardial infarction. New England Journal of Medicine 356: 1723-1735.
4. Calmy A, Gayet-Ageron A, Montecucco F, Nguyen A, Mach F, et al. (2009) HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 23: 929-939.
5. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, et al. (2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5: e203.
6. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, et al. (2006) CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355: 2283-2296.
7. Grunfeld C, Delaney JAC, Wanke C, Currier JS, Scherzer R, et al. (2009) Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 23: 1841-1849.
8. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, et al. (2003) Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. Journal of the American College of Cardiology 41: 1769-1775.
9. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, et al. (2000) Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101: 948-954.
10. Kang SM, Chung N, Kim JY, Koo BK, Choi D, et al. (2002) Relation of vasodilator response of the brachial artery to inflammatory markers in patients with coronary artery disease. Echocardiography 19: 661-667.
11. Suessenbacher A, Frick M, Alber HF, Barbieri V, Pachinger O, et al. (2006) Association of improvement of brachial artery flow-mediated vasodilation with cardiovascular events. Vasc Med 11: 239-244.
12. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R, (2002) Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. Journal of the American College of Cardiology 40: 505-510.
13. Green LA, Kim C, Gupta SK, Rajashekhar G, Rehman J,et al. (2012, in press) Pentoxifylline Reduces Tumor Necrosis Factor-alpha and HIV-Induced Vascular Endothelial Activation. AIDS Research and Human Retroviruses.
14. Gupta SK, Johnson RM, Mather KJ, Clauss M, Rehman J, et al. (2010) Anti-inflammatory treatment with pentoxifylline improves HIV-related endothelial dysfunction: a pilot study. AIDS 24: 1377-1380.
15. Hsue PY, Hunt PW, Wu Y, Schnell A, Ho JE, et al. (2009) Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 23: 2021-2027.
16. Gupta SK, Shen C, Moe SM, Kamendulis LM, Goldman M,et al. (2012, in press.) Worsening endothelial function with efavirenz compared to protease inhibitors: A 12-month prospective study. PLOS ONE.
17. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, et al. (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. Journal of the American College of Cardiology 39: 257-265.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
19. Lachin JM, (1999) Worst-rank score analysis with informatively missing observations in clinical trials. Controlled Clinical Trials 20: 408-422.
20. Berger VW, Exner DV, (1999) Detecting selection bias in randomized clinical trials. Controlled Clinical Trials 20: 319-327.
21. Dezube BJ, Lederman MM, (1995) Pentoxifylline for the treatment of HIV infection and its complications. Journal of Cardiovascular Pharmacology 25Suppl 2: S139-142.
22. Dezube BJ, Lederman MM, Spritzler JG, Chapman B, Korvick JA, et al. (1995) High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. Journal of Infectious Diseases 171: 1628-1632.
23. Dezube BJ, Pardee AB, Chapman B, Beckett LA, Korvick JA, et al. (1993) Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group. Journal of Acquired Immune Deficiency Syndromes 6: 787-794.
24. Fazely F, Dezube BJ, Allen-Ryan J, Pardee AB, Ruprecht RM, (1991) Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T cells. Blood 77: 1653-1656.
25. Clerici M, Piconi S, Balotta C, Trabattoni D, Capetti A, et al. (1997) Pentoxifylline improves cell-mediated immunity and reduces human immunodeficiency virus (HIV) plasma viremia in asymptomatic HIV-seropositive persons. Journal of Infectious Diseases 175: 1210-1215.
26. Bilsborough W, O'Driscoll G, Stanton K, Weerasooriya R, Dembo L, et al. (2002) Effect of lowering tumour necrosis factor-alpha on vascular endothelial function in Type II diabetes. Clin Sci 103: 163-169.